此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

GCAR1,一种用于复发/难治性GPNMB表达实体瘤的嵌合抗原受体(CAR)T细胞疗法

2026年11月10日 更新者:Canadian Cancer Trials Group

一项针对特定复发/难治性GPNMB表达实体瘤患者的嵌合抗原受体(CAR)T细胞疗法GCAR1的I期研究

Only enrolling in Canada.

The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

研究概览

详细说明

GCAR1 is a type of CAR-T cell therapy that is designed to identify a protein (GPNMB) that is present on the cells of certain types of cancer. Laboratory tests have shown that GCAR1 helps the immune system recognize cancer cells and may help slow down cancer growth.

The purpose of this study is to find out what effects the new treatment, GCAR1 has on certain cancers. This study will test increasing doses of GCAR1 in participants with alveolar soft part sarcoma (ASPS), triple negative breast cancer (TNBC), and renal cell carcinoma (RCC) expressing high levels of the GPNMB protein, to establish recommended doses for further testing.

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T2N 5G2
        • 招聘中
        • Arthur J.E. Child Comprehensive Cancer Centre
        • 接触:
          • Mona Shafey
          • 电话号码:403 944-8047
    • Ontario
      • Ottawa、Ontario、加拿大、K1H 8L6
        • 招聘中
        • Ottawa Hospital Research Institute
        • 接触:
          • Natasha Kekre
          • 电话号码:71064 613 737-8899
      • Toronto、Ontario、加拿大、M5G 2M9
        • 招聘中
        • University Health Network
        • 接触:
          • Abdulazeez Salawu
          • 电话号码:416 946-4501
    • Quebec
      • Montreal、Quebec、加拿大、H4A 3J1
        • 招聘中
        • The Research Institute of the McGill University
        • 接触:
          • Ramy Saleh

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

15年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Archival tumour specimen must be positive for GPNMB with high expression by immunohistochemistry (central laboratory testing).

  • Histologically and/or cytologically confirmed diagnosis of one of the following tumours that is advanced/ metastatic/ recurrent or unresectable, for which no curative therapy exists.

  • alveolar soft part sarcoma

  • renal cell carcinoma (excluding clear cell)

  • triple negative breast cancer (ER, PR and HER-2 negative as defined by ASCO/CAP criteria)

  • Must have a formalin fixed paraffin embedded tissue block (from primary or metastatic tumour) available and must have provided informed consent for the release of the block.

  • Presence of radiologically documented disease.

  • Measurable disease as defined by RECIST 1.1.

  • ASPS participants ≥ 15 years of age.

  • TNBC and RCC participants ≥ 18 years of age.

  • ECOG performance status of 0 or 1 or Karnofsky or Lansky > 60.

  • Anticipated life expectancy of ≥ 6 months.

  • Must have received prior systemic therapy as shown below;

  • ASPS - completed all systemic therapy available that has been shown to improve survival (unless contraindicated).

  • TNBC

    1. Progressive disease following at least one line of systemic treatment for metastatic disease which must include an ADC (all participants) and an ICI (participants whose tumours express PD-L1).
    2. ≤3 lines of treatment for metastatic disease.
    3. Must have had at least 1 prior line of cytotoxic chemotherapy for breast cancer, in any setting, which must have included an anthracycline and a taxane (unless contraindicated).
  • RCC - must have progressive disease following at least one line of systemic treatment for metastatic disease that must have included an ICI and a VEGFR targeted agent (unless contraindicated).

  • Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior therapies.

  • Adequate washout must be followed per protocol.

  • Previous major surgery is permitted ≥21 days prior to enrollment

  • Prior external beam radiation is permitted ≥28 prior to enrollment. Concurrent radiotherapy is not permitted.

  • Adequate hematologic and biochemical parameters.

  • Consent and assent, when applicable, must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant or their parent/ legal guardian (if applicable) must sign a consent form prior to screening onto the trial to document their willingness to participate.

  • Fit for leukapheresis and has adequate venous access for cell collection.

  • Must be accessible for treatment and follow up at the participating centre for a minimum of 12 months or for as long as is deemed necessary by the treating physician.

  • Participants of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion criteria

  • Participants on active anticancer therapy for other advanced or metastatic malignancies.
  • Concurrent treatment with other anti-cancer therapy
  • Prior therapy with a gene therapy product or any adoptive T cell therapy or prior GPNMB targeting therapy.
  • Live attenuated vaccination administered within 30 days prior to or planned within 30 days after GCAR1 therapy.
  • Primary immunodeficiency or history of severe autoimmune disease (including: Crohn's disease, rheumatoid arthritis, systemic lupus) requiring immunosuppressive agents/ systemic disease modifying agents within 2 years of enrollment.
  • Active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the participant to be managed according to the protocol including but not limited to:
  • Hepatitis B or C virus (HBV or HCV). For participants with previous HBV or HCV infection who are currently on treatment, they are eligible if they have an undetectable viral load via quantitative PCR and/or nucleic acid testing
  • HIV
  • Uncontrolled fungal, bacterial, viral or other infection
  • Current infection with HTLV
  • Tuberculosis
  • Syphilis
  • West Nile Virus
  • Untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction (including cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects) or unstable angina congestive heart failure or myocardial infarction within the previous year.
  • Known sensitivity or allergy to fludarabine, cyclophosphamide or any of their components, or to GCAR1 or any of its components.
  • Active intracerebral metastases or leptomeningeal disease. Participants who have received definitive treatment, are clinically stable and do not require corticosteroids are eligible to participate in the trial.
  • Pregnant or breastfeeding women.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:GCAR1输注

Assigned at enrollment

Assigned at enrollment

Dose escalation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapy
大体时间:3 years

(GCAR1) in participants with selected tumours (alveolar soft part sarcoma, renal cell carcinoma (excluding clear cell), triple negative breast cancer) expressing GPNMB

3 years

次要结果测量

结果测量
大体时间
反应持续时间
大体时间:3年
3年
使用CTCAE v5.0评估的不良事件数量和严重程度GCAR1
大体时间:3年
3年
根据RECIST 1.1标准的总体缓解率
大体时间:3年
3年

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Mona Shafey、Tom Baker Cancer Centre, Calgary, Alberta, Canada

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月30日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2033年9月1日

研究注册日期

首次提交

2025年12月9日

首先提交符合 QC 标准的

2025年12月9日

首次发布 (实际的)

2025年12月22日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅